



UNIVERSITY OF LEEDS

This is a repository copy of *Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/119692/>

Version: Supplemental Material

Article:

Lardas, M, Liew, M, van den Bergh, R et al. (21 more authors) (2017) Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. *European Urology*, 72 (6). pp. 869-885. ISSN 0302-2838

<https://doi.org/10.1016/j.eururo.2017.06.035>

(c) 2017, European Association of Urology. Published by Elsevier B.V. This manuscript version is made available under the CC BY-NC-ND 4.0 license
<https://creativecommons.org/licenses/by-nc-nd/4.0/>

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Table 4: Visual Table for results from prospective studies

Author, (longest follow-up time), Questionnaire used	Intervention	N at baseline	Reported results ¹ (table presents latest follow up data of each study)							
Studies that report change in QoL scores BETWEEN groups										
Bacon 2001 [14] (60 months) UCLA PCI <u>RP reference</u>	Radical prostatectomy	421	Urinary function	Urinary bother	Bowel function	Bowel bother	Sexual function	Sexual bother		
	Radiotherapy	221	Urinary function	Urinary bother	Bowel function	Bowel bother	Sexual function	Sexual bother		
	Brachytherapy	69	Urinary function	Urinary bother	Bowel function	Bowel bother	Sexual function	Sexual bother		
Barocas 2017 [30] (36 months) EPIC	Radical prostatectomy	1523	Urinary incontinence*	urinary irritation*	Bowel function	Sexual function	Hormone function			
	Radiotherapy	598	Urinary incontinence*	urinary irritation*	Bowel function	Sexual function	Hormone function			
Borchers 2004 [15] (12 months) EORTC-QLQ-C30 <u>Brachytherapy reference</u>	NS Radical prostatectomy	38	Physical functioning	Role functioning	Emotional functioning	Cognitive functioning	Social functioning	Sexual functioning	Overall	
	Non NS Radical prostatectomy	42	Physical functioning	Role functioning	Emotional functioning	Cognitive functioning	Social functioning	Sexual functioning	Overall	
	Brachytherapy	52	Physical functioning	Role functioning	Emotional functioning	Cognitive functioning	Social functioning	Sexual functioning	Overall	
Evans 2015 [16] (24 months) EPIC <u>Brachytherapy reference</u>	Brachytherapy	262	Urinary incontinence*	Urinary obstruction*	Bowel summary	Sexual summary	Hormone summary			
	IMRT	160	Urinary incontinence*	Urinary obstruction*	Bowel summary	Sexual summary	Hormone summary			
	SBRT	381	Urinary incontinence*	Urinary obstruction*	Bowel summary	Sexual summary	Hormone summary			

Table 4: Visual Table for results from prospective studies

Jeldres 2015 [17] (36 months) EPIC	Active Surveillance	77	Urinary function	Urinary bother	Bowel function	Bowel bother	Sexual function	Sexual bother	Hormone function	Hormone bother
	Radical Prostatectomy	228	Urinary function	Urinary bother	Bowel function	Bowel bother	Sexual function	Sexual bother	Hormone function	Hormone bother
Kobuke 2009 [18] (12 months) UCLA-PCI	Radical prostatectomy	37	Urinary function	Urinary bother	Bowel function	Bowel bother	Sexual function	Sexual bother		
	Brachytherapy	36	Urinary function	Urinary bother	Bowel function	Bowel bother	Sexual function	Sexual bother		
Namiki 2006 [20] (12 months) UCLA-PCI	Radical prostatectomy	67	Urinary function	Urinary bother	Bowel function	Bowel bother	Sexual function	Sexual bother		
	Brachytherapy	70	Urinary function	Urinary bother	Bowel function	Bowel bother	Sexual function	Sexual bother		
Pardo 2010 [21] (36 months) EPIC <u>RP reference</u>	Radical prostatectomy	123	Urinary incontinence*	Urinary obstruction*	Bowel summary	Sexual summary	Hormonal summary			
	External-beam radiotherapy	127	Urinary incontinence*	Urinary obstruction* (compared with NSRP only)	Bowel summary (compared with non-NSRP only)	Sexual summary	Hormonal summary (compared with NSRP only)			
	Brachytherapy	185	Urinary incontinence*	Urinary obstruction* (compared with NSRP only)	Bowel summary	Sexual summary	Hormonal summary			
Pinkawa 2009 [22]	Brachytherapy	52	Urinary incontinence bother*	Urinary obstructive - irritative bother*	Bowel function	Bowel bother	Sexual function	Sexual bother	Hormonal function	Hormonal bother

Table 4: Visual Table for results from prospective studies

(16 months) EPIC	External beam radiotherapy	52	Urinary incontinence bother*	Urinary obstructive - irritative bother*	Bowel function	Bowel bother	Sexual function	Sexual bother	Hormonal function	Hormonal bother
Punnen 2014 [25] (120 months)	NS Radical prostatectomy	1139	Urinary function	Urinary bother	Bowel function	Bowel bother	Sexual function	Sexual bother		
	Non NS Radical prostatectomy	860	Urinary function	Urinary bother	Bowel function	Bowel bother	Sexual function	Sexual bother		
	UCLA-PCI									
	<u>NSRP reference</u>									
	Brachytherapy	684	Urinary function	Urinary bother	Bowel function	Bowel bother	Sexual function	Sexual bother		
	EBRT	386	Urinary function	Urinary bother	Bowel function	Bowel bother	Sexual function	Sexual bother		
Resnick 2013 [26] (180 months) PCOS questionnaire	Radical prostatectomy	1164	Urinary incontinence	Bowel function	Sexual function					
	EBRT	491	Urinary incontinence	Bowel function	Sexual function					
Schapira 2001 [28] (12 months) UCLA-PCI	Radical prostatectomy	42	Urinary function	Urinary bother	Bowel function	Bowel bother	Sexual function	Sexual bother		
	Radiotherapy	51	Urinary function	Urinary bother	Bowel function	Bowel bother	Sexual function	Sexual bother		
Studies that report change in QoL scores WITHIN groups										
Sanda 2008 [27] (24 months) EPIC	Radical prostatectomy	603	Urinary Incontinence*	Urinary obstructive - Irritative*	Bowel function	Sexual function	Hormonal function			
	EBRT	292	Urinary Incontinence*	Urinary obstructive - Irritative*	Bowel function	Sexual function <u>(only for EBRT plus NHT)</u>	Hormonal function <u>(only for EBRT plus NHT)</u>			

Table 4: Visual Table for results from prospective studies

	Brachytherapy	306	Urinary Incontinence*	Urinary obstructive - Irritative*	Bowel function	Sexual function	Hormonal function			

Red: statistically significant deterioration

Orange: statistically significant deterioration, however the difference between groups or within groups does not exceed the minimally important difference for clinical significance, as defined by authors. This is applicable only for studies reporting minimally important difference for clinical significance

Green: statistically significant improvement

White: no statistically significant difference (For studies comparing interventions, it corresponds to the intervention used as reference and to those that do not show significant difference with this reference; for studies that report changes in QoL within groups, it shows intervention for which the QoL did not show significant change over time)

RP: Radical prostatectomy

NSRP: Nerve-sparing radical prostatectomy

EBRT: External beam radiotherapy

NHT: Neoadjuvant hormone therapy

* In EPIC questionnaire urinary function items and bother items are combined in the urinary incontinence subscale and the urinary irritation/obstruction subscale.

1. Malcolm study is not presented in the table as authors report p values for between group comparisons taking into consideration the cryotherapy arm which we are not including in our review. Symon study is also not presented in the table as authors do not report differences in disease-specific QoL scores among different treatments.